Quantum BioPharma's Lucid-MS Advances to Phase 2, Drawing Analyst Buy Rating

Quantum BioPharma Ltd. (NASDAQ: QNTM) has received U.S. Food and Drug Administration clearance to initiate a Phase 2 clinical trial for its lead drug candidate, Lucid-MS, a patented new chemical entity designed to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The milestone was highlighted in a BioMedWire editorial titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” which examined the significance of the FDA decision for the small-cap biotechnology company.

Lucid-MS represents a departure from conventional multiple sclerosis therapies, which primarily target the immune system. Instead, the compound is designed to protect and potentially repair the myelin sheath, a fatty substance that insulates nerve fibers and is progressively damaged in MS patients. This first-in-class mechanism could offer a complementary or alternative approach for patients who do not respond adequately to existing immunomodulatory treatments. Preclinical models have shown that Lucid-MS can both prevent and reverse myelin degradation, according to the company.

The FDA clearance has already influenced market sentiment. The BioMedWire editorial noted that the Phase 2 milestone has drawn a new buy rating from Wall Street analysts, suggesting growing confidence in the drug’s commercial potential. For a micro-cap biotech, advancing a novel candidate into mid-stage clinical trials is a significant achievement that most companies never reach, and it validates Quantum’s research and development strategy.

Quantum BioPharma operates through its wholly owned subsidiary, Lucid Psycheceuticals Inc., which is focused on the research and development of Lucid-MS. The company is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. In addition to Lucid-MS, Quantum invented UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

The Phase 2 trial for Lucid-MS will be closely watched by investors and the medical community. If successful, it could position Quantum as a key player in the multiple sclerosis treatment landscape, where new mechanisms of action are urgently needed. The company’s newsroom, available at https://ibn.fm/QNTM, provides ongoing updates. The full press release can be viewed at https://ibn.fm/dwwiP. BioMedWire, a specialized communications platform for the biotechnology and life sciences sectors, published the editorial. More information about BioMedWire is available at https://www.BioMedWire.com, and terms of use and disclaimers can be found at https://www.BioMedWire.com/Disclaimer.